LEADER 01708nam  2200421 a 450 
001 9910695346103321
005 20061012153533.0
035   $a(CKB)5470000002369290
035   $a(OCoLC)72707052
035   $a(EXLCZ)995470000002369290
100   $a20061012d2006      ua             0
101 0 $aeng
135   $aurmn|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMedicare Part B drugs$b[electronic resource] $eCMS data source for setting payments is practical but concerns remain : testimony before the Subcommittee on Health, Committee on Ways and Means, House of Representatives /$fstatement of A. Bruce Steinwald
210  1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2006]
215   $a9 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-06-971 T
300   $aTitle from title screen (viewed on Oct. 11, 2006).
300   $a"For release ... July 13, 2006."
300   $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aMedicare Part B drugs 
606   $aMedicare$xEconomic aspects
606   $aDrugs$xPrices$zUnited States
615  0$aMedicare$xEconomic aspects.
615  0$aDrugs$xPrices
700   $aSteinwald$b Bruce$01381591
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Ways and Means.$bSubcommittee on Health.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910695346103321
996   $aMedicare Part B drugs$93424343
997   $aUNINA